Plasmodium vivax resistance to chloroquine (R2) and mefloquine (R3) in Brazilian Amazon region

We report for the first time a patient with malaria due to Plasmodium vivax who showed R2 resistance to chloroquine and R3 resistance to mefloquine in the Brazilian Amazon region based on WHO clinical criteria for diagnosis of malaria resistance. Failure was observed with unsupervised oral chloroqui...

Full description

Saved in:

Bibliographic Details
Published in:	Revista da Sociedade Brasileira de Medicina Tropical Vol. 32; no. 1; pp. 67 - 68
Main Authors:	Alecrim M das, G, Alecrim, W, Macêdo, V
Format:	Journal Article
Language:	English
Published:	Brazil Sociedade Brasileira de Medicina Tropical 1999 Sociedade Brasileira de Medicina Tropical - SBMT
Subjects:	Animals Antimalarials - therapeutic use Artemisinins Artesunate Brazil Child Chloroquine - therapeutic use Drug Resistance Female Humans Malaria Malaria - drug therapy Mefloquine - therapeutic use Plasmodium vivax - drug effects Sesquiterpenes - therapeutic use TROPICAL MEDICINE Vector-borne diseases Plasmodium vivax Resistência a drogas Resistência à cloroquina Resistência à mefloquina Chloroquine resistance Drug resistance Mefloquine resistance
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We report for the first time a patient with malaria due to Plasmodium vivax who showed R2 resistance to chloroquine and R3 resistance to mefloquine in the Brazilian Amazon region based on WHO clinical criteria for diagnosis of malaria resistance. Failure was observed with unsupervised oral chloroquine, chloroquine under rigorous supervision and mefloquine in the same scheme. Finally, the patient was cured with oral artesunate.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	0037-8682 1678-9849 0037-8682 1678-9849
DOI:	10.1590/S0037-86821999000100013